Pricing

Outlook Therapeutics Inc (OTLK)

followers ·
Sector: HEALTH CARE
Industry: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO: C. Russell Trenary
Employees: 20
Web site: outlooktherapeutics.com
485 ROUTE 1 SOUTH, BUILDING F, SUITE 320, ISELIN, NJ, 08830
6096193990
Stock Split History
Date Ratio
2019-03-18 1:8
2024-03-14 1:20
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Outlook Therapeutics, Inc. focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available